Business
RepliCel Life Sciences Inc. announces Brokered Private Placement
RepliCel Life Sciences Inc. announces Brokered Private Placement.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel Life Sciences Inc. announces Brokered Private Placement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel Life Sciences Inc. announces Brokered Private Placement\nCanada NewsWire\nVANCOUVER, Feb. 7, 2017\n\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\n\n\n\nVANCOUVER, Feb. 7, 2017 /CNW/- RepliCel Life Sciences Inc. (\"RepliCel\" or the \"Company\") (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce that it has appointed a syndicate of agents co-led by Echelon Wealth Partners Inc. (\"Echelon\") and Haywood Securities Inc. (\"Haywood\"), with participation from Clarus Securities Inc. (\"Clarus\", together with Echelon and Haywood, the \"Agents\"), to undertake a brokered private placement (the \"Offering\"), on a commercially reasonable basis, of up to 1,600,000 units (each, a \"Unit\"), at a price of $1.25 per Unit. \n\nEach Unit will consist of one common share of the Company (each, a \"Common Share\") and one Common Share purchase warrant (each, a \"Warrant\"), with each Warrant entitling the holder to purchase one additional Common Share at a price of $2.00 per Common Share for a period of three (3) years from the closing of the Offering. Echelon will act as the sole bookrunner for the Offering. \n\nAll securities issued pursuant to the Offering will be subject to a statutory hold period expiring four months and one day after closing of the Offering. Completion of the Offering is subject to a number of conditions, including, without limitation, entry into an agency agreement with the Agents and receipt of all regulatory approvals, including approval of the TSX Venture Exchange.\n\nProceeds of the Offering are anticipated to be used for clinical trials, research and development, device manufacturing and testing and general working capital.\n\nNone of the securities issued in connection with the Offering will be registered under the United States Securit...